Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Price Target at $13.50

by · The Cerbat Gem

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $13.50.

A number of research firms recently commented on AMRX. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, October 8th. JPMorgan Chase & Co. increased their price objective on Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Piper Sandler restated an “overweight” rating and issued a $13.00 target price (up from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. Finally, Barclays started coverage on Amneal Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $15.00 price target for the company.

View Our Latest Stock Report on Amneal Pharmaceuticals

Insider Transactions at Amneal Pharmaceuticals

In other news, Director Ted C. Nark sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $11.72, for a total value of $586,000.00. Following the completion of the transaction, the director owned 291,029 shares in the company, valued at $3,410,859.88. This trade represents a 14.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Nikita Shah sold 131,856 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the sale, the executive vice president owned 146,403 shares in the company, valued at $1,745,123.76. The trade was a 47.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 231,856 shares of company stock valued at $2,743,724 in the last quarter. Company insiders own 26.56% of the company’s stock.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Large investors have recently made changes to their positions in the stock. BlackBarn Capital Partners LP boosted its position in Amneal Pharmaceuticals by 19.6% during the second quarter. BlackBarn Capital Partners LP now owns 3,446,570 shares of the company’s stock valued at $27,883,000 after buying an additional 564,916 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Amneal Pharmaceuticals by 22.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,332,366 shares of the company’s stock valued at $10,779,000 after acquiring an additional 240,676 shares during the last quarter. Walleye Capital LLC boosted its holdings in Amneal Pharmaceuticals by 26.9% during the 2nd quarter. Walleye Capital LLC now owns 708,946 shares of the company’s stock valued at $5,735,000 after acquiring an additional 150,104 shares during the period. Acadian Asset Management LLC boosted its holdings in Amneal Pharmaceuticals by 51.3% during the 1st quarter. Acadian Asset Management LLC now owns 2,598,294 shares of the company’s stock valued at $21,759,000 after acquiring an additional 880,471 shares during the period. Finally, Squarepoint Ops LLC grew its position in Amneal Pharmaceuticals by 276.3% during the 2nd quarter. Squarepoint Ops LLC now owns 572,548 shares of the company’s stock worth $4,632,000 after acquiring an additional 420,398 shares during the last quarter. 31.82% of the stock is owned by institutional investors.

Amneal Pharmaceuticals Price Performance

Shares of Amneal Pharmaceuticals stock opened at $12.95 on Thursday. The firm has a market cap of $4.07 billion, a PE ratio of 647.82 and a beta of 1.36. Amneal Pharmaceuticals has a 1 year low of $6.68 and a 1 year high of $13.01. The stock has a fifty day moving average price of $11.75 and a 200-day moving average price of $9.96.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.05. Amneal Pharmaceuticals had a net margin of 0.20% and a negative return on equity of 185.60%. The company had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. As a group, equities analysts anticipate that Amneal Pharmaceuticals will post 0.53 EPS for the current fiscal year.

Amneal Pharmaceuticals Company Profile

(Get Free Report)

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

Featured Articles